W1265 Infliximab in Combination with Immunomodulators in the Treatment of Children with Crohn's Disease: Advantages and Risks
about
W1265 Infliximab in Combination with Immunomodulators in the Treatment of Children with Crohn's Disease: Advantages and Risks
description
im April 2008 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2008
@uk
name
W1265 Infliximab in Combinatio ...... Disease: Advantages and Risks
@en
W1265 Infliximab in Combinatio ...... Disease: Advantages and Risks
@nl
type
label
W1265 Infliximab in Combinatio ...... Disease: Advantages and Risks
@en
W1265 Infliximab in Combinatio ...... Disease: Advantages and Risks
@nl
prefLabel
W1265 Infliximab in Combinatio ...... Disease: Advantages and Risks
@en
W1265 Infliximab in Combinatio ...... Disease: Advantages and Risks
@nl
P2093
P1433
P1476
W1265 Infliximab in Combinatio ...... Disease: Advantages and Risks
@en
P2093
Gigi Veereman
Isabelle Paquot
Philippe Alliet
Tania Mahler
P356
10.1016/S0016-5085(08)63116-9
P407
P577
2008-04-01T00:00:00Z